Connect with us

Cannabis News

Trucking Industry Group Is ‘Deeply Concerned’ About Marijuana Rescheduling’s Potential Impact On Drug Testing For Drivers

Published

on

American truck associations (ATA) say that “very worried” is in drug testing programs.

Sean Duffy Sean Duffy, Dan Horvath, said Dan Horvath. Dan Horvath is capable of achieving the authority and ability to control the transport employees of the marijuana commercial engine (CMV) and security staff “.

Of course, this policy has not yet been prescribed. And while President Donald Trump said he will take a decision about the recently mentioned proposal in the week-Txo protect the reform on the route of the campaign last year – should be seen whether he wants to continue the restoration.

Horvath said that the door “does not have a formal position to legalize or deregulation,” we are very worried about re-programming safety risks, testing the authority and technical requirements for the necessary security staff. “

Concern is a potential guideline for the compulsory federal drug test if they will now be transferred to the Cannabis III Program.

“If so, dot programs to keep programs without cleaning, to maintain marijuana testing authority, and such federal policy changes can be serious consequences for highway safety and national transport network,” letters said. “This risk is not a proven standard, a highly accepted standard before the roadside or before the driver starts working before the vehicle is harder to prevent driving disability.”

“The implications of a gap in the test authority are well documented in the implications of potential security,” Horvath said, pointing to the data The rate of Positive Thc among the driver And research showed the increase in traffic death after state legalization.

“The door has repeatedly transmitted these concerns, and our demand about potential clarity, in the DOT test program, according to the previous administration, both in discussions about formal letters and people”. new According to transport issues.

Horvath also noticed Pete Buttigieg while the Secretary of Transportation has told a conference committee last year Rescheduling would not affect drug testing regulationsAta “never received Answer to our correspondence Explain the basis of this position or explain the details that intend to deal with impacts in the program. “

“The public attention of marijuana policy and marijuana is a federal novelty, we want to effectively coordinate the change in the HHS (Department of Justice) to ensure the authority, tools and technical skills in controlling federal policy.”

Meanwhile, a policy in a couple of companies in the truck industry premiered in April, which sought was approximately 80,000 drivers Positive to marijuana says staff had aggravated Zero-tolerance drug policy below dot.

MARIHUANA Moving III “dot regulations and drug test protocols”, papers, for example, recognizing legal medical use and reducing social stigma, but should not be facilitated.

Dot drug screening program usually uses urinary-based tests, but the report says that Saliva and hair follicle test provides benefits in this standard. It is warned that “there is no extended test today to determine whether a driver is exposed to a drug like THC.”

The Department ended the new test policy in 2023 Allow oral salt drug testing as an alternative to testing based on urine. Late Last last year, critics fell more than half years after the end of the authority, Fixed officials had yet to use the necessary infrastructure to use the new test procedure.

Legislators of Congress Auditions in March The truck industry representatives heard that they called the use of hair follicle tests in the industry. President of the National Transport Safety Commission (NTSB) recommended better education for drivers.

In April, the US Supreme Court A Cannabis company sued for a truck after shooting for a positive THC test He said consuming the CBD product derived from hemp.

Separately, substance abuse and mental health services administration (Samhsa) Official Criticism of a drug testing drug testing “means a drug test” means Canavies use cannabis to do with the nearby impunityA couple of days while avoiding drug test. “

The Transport Industry also recommended the Congress in January If Marijuana is federally restructuring, businesses do not ensure that zero tolerance policies do not need drivers-The key problem of the questionnaire is lacking technology to detect driving handicap.

Report of the 2023 Congress of Congress of Transport, Housing and Urban Development and Related Agencies (Thud), the House Credit Committee “Marijuana impairment measurement measurement is continued to measure the measurement test measurement of sobriety tests to ensure highway security. “

A year earlier in Colorado John Hickenlooper (D) Senin sent the letter to the point Looking for an update in this state of a federal report In the roads that inhibit the development of standardized marijuana deterioration on the roads. The Department Report had to complete Under a large-scale infrastructure bill Then signed by President Joe Biden, but The deadline he reported.

Meanwhile, the National Transport Safety Commission (NTSB) warned Marijuana again program “blind places” to test federally regulated employee tests in security sensitive positions.

On the home committee, then the Dot Secretary mentioned concerns about the door “about the general public” Effects of Highway National System Appeal and Safety Conclusions And his users, “Truck Associations were thrown in a letter to the secretary.

The current federal laws promise to abstain by commercial drivers from cannabis to different types of drug performances, pre-work, random tests.

In June 2022, they found the ATRI survey of the US Licensed Truck Drivers 72.4 percent “release” supports cannabis law and test policies. Another 66.5, 66.5 said Marijuana had to be legalized federally.

Cannabis deforms reforms, while, too The federal civil servant called the “discriminatory” drug test practice around the truck industry.

Fargo Analysis A top well said in 2022 that the main reason for raising costs and staff in the transport sector: marijuana criminalization and As a result, drug testing orders This follows as more states legalize.

Later representative. Earl Blumenoer (or) sent a letter to Motura in 2022, emphasizing that they are policies about the drug testing truck and commercial marijuana useless people cost their work And it helps supply chain problems.

2022 ATRI reports that the impact of cannabis is affected and the impact on motorway security is currently confused, complicating the judgment to correct the problem. A separate 2019 Congress Research Service Report (CRS) It has also been found that evidence of the decline in cannabis is not inclusive.

Read ata’s print Maryhuana rewrite and drug testing followed:

Marijuana is possible with the help of readers. If you are based on journalism to defend cannabis, consider the commitment to Patreon every month.

(Tagstotranslate) highlighted

Continue Reading

Cannabis News

Tilray Medical announces commercial launch of medical cannabis in Panama

Published

on

By

Tilray Medical has announced the launch of its first medical cannabis product in Panama, part of the company’s continued global expansion and commitment to improving patient access to pharmaceutical grade cannabinoids worldwide.

Following the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical’s EU-GMP certified production facilities in Portugal through a joint venture with Solana Life Group S. de RL, the Product is to be distributed through Farmacias Arrocha, one of the leading pharmaceutical chains in Panama, where patients will be able to access Tilray Oral Solution CBD with medical prescription100. This is expected to provide patients and healthcare professionals with access to regulated medical cannabis of pharmaceutical quality through established healthcare channels.

Rajnish Ohri, International President, Tilray Brands, said: “At Tilray Medical, we believe that every patient deserves access to safe, consistent, pharmaceutical-grade cannabis products. The launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines around the world. We want pharmacists and patients to help shape the future of responsible access, advance medical education and provide high-quality treatment options that improve lives.”

The launch supports the Panamanian medical cannabis framework established by Law 242 of 2021 and follows important regulatory advances made by the Ministry of Health, including No. 0406 of May 12, 2026. The decision, which established the main conditions for the admission of patients. The Ministry also recently introduced the System for the Identification of Medical Cannabis Users and Authorized Caregivers (SIUCMAA), creating a structured way to authorize medical practitioners and register patients.

Manufactured in Portugal under strict European Union Good Manufacturing Practice (EU-GMP) standards, Tilray Oral Solution CBD100 is intended for use in patients with qualified medical conditions permitted under Panamanian law, where permitted. The products reflect Tilray Medical’s longstanding commitment to pharmaceutical quality, product consistency, patient safety and regulatory compliance.

Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a strategic global export hub, supplying EU-GMP certified medical cannabis products to regulated markets worldwide. The platform enables Tilray Medical to effectively support growing international demand while maintaining the highest pharmaceutical manufacturing standards across its global operations.

For more information:
Tilray
www.tilray.com

Continue Reading

Cannabis News

Medical Marijuana Is ‘Effective’ In Providing Relief To Patients With Restless Legs Syndrome, Study Shows

Published

on

By

People with restless leg syndrome (RLS) may find “significant” long-term relief with cannabis treatment, according to a new study.

While dopamine agonists have traditionally been the “first-line treatment” for RLS, recent studies indicate that gabapentinoids are now being recommended, the researchers said. Because cannabinoids, like gabapentinoids, inhibit a certain type of amino acid associated with the disorder, scientists decided to test their therapeutic effectiveness.

The open-label exploratory study, conducted by European researchers at the University of Madrid and published in the Journal of Neurology, found that a cannabis product containing 2.7 mg of THC and 2.5 mg of CBD was “effective in reducing RLS severity” among patients with multiple sclerosis and “associated idiopathic RLS.”

“Improvements were observed after 1 to 3 months of treatment and were maintained after 1 year among patients who continued therapy,” the study of 18 patients with RLS showed. For those who remained in treatment after a year, 67 percent “continued to show sustained improvement.”

The the findings it may not be surprising that cannabis in particular is known to reduce the severity of muscle spasms and related conditions, but its effectiveness for RLS is remarkable given that no state specifically lists it as a condition for medical cannabis.

Of course, RLS can be a symptom of other general disorders like multiple sclerosis, and some states give doctors more latitude to make recommendations for medical marijuana for any condition they see fit.

In any case, research outside of Spain could be based on research into alternative treatment options that could replace dopamine agonists in the treatment of restless legs syndrome.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Wyoming AG keeps cannabis on Schedule I, rejects federal reclassification

Published

on

By











Wyoming Attorney General Keith Kautz announced on July 7 that he would keep all marijuana products in Schedule I of Wyoming’s Controlled Substances Act, refusing to align the state’s cannabis policy with the federal reorganization order issued earlier this year.

Kautz, who also serves as Wyoming’s drug and substance abuse commissioner, held a public hearing on June 18 after filing an objection to aligning the state’s cannabis schedule with a federal amendment on May 27. State law requires the commissioner to give interested parties an opportunity to be heard after that objection, but only nine people responded. Four email comments supported leaving cannabis as a Schedule I drug, four as Schedule III. It was approved for use and one person attended the hearing to request that cannabis remain in Schedule I.

His decision follows an April 2026 order signed by U.S. Attorney General Todd Blanche that bans state-licensed medical cannabis, FDA-approved cannabis products, cannabis extracts and naturally derived delta-9 THC III.

Kautz’s office says: “After consideration of all stakeholder comments, the commissioner has determined that all marijuana products, including marijuana subject to the state’s medical marijuana license, will remain in Schedule I of the Wyoming Controlled Substances Act.”

His announcement adds, “The decision to reschedule medical marijuana and marijuana products is an important policy decision that is best left to the Wyoming Legislature and should not be made through administrative rule.”

Wyoming remains one of eight states without a medical cannabis program. A December 2020 poll by the University of Wyoming’s Wyoming Center for Polling and Analysis found that 85 percent of state residents support legalizing medical cannabis, despite a failed 2024 ballot initiative effort. Possession of three ounces or less carries up to 12 months in prison under current state law, and selling any amount is punishable by up to 10 years in prison and a $10,000 fine.

Kautz says his office will “properly schedule products approved by the United States Food and Drug Administration once that agency has approved the product,” pointing to the Schedules II and III listings of Cesamet and Dronabinol as evidence that the state complies with federal cannabinoid drug law.










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media